Iovance Biotherapeutics Inc’s recent filing unveils that its Director Rothbaum Wayne P. acquired Company’s shares for reported $45.75 million on Feb 20 ’24. In the deal valued at $9.15 per share,5,000,000 shares were bought. As a result of this transaction, Rothbaum Wayne P. now holds 28,067,333 shares worth roughly $382.56 million.
Then, MCPEAK MERRILL A bought 250,000 shares, generating $2,287,500 in total proceeds. Upon buying the shares at $9.15, the Director now owns 320,150 shares.
Before that, Dukes Iain D. bought 32,000 shares. Iovance Biotherapeutics Inc shares valued at $292,800 were divested by the Director at a price of $9.15 per share. As a result of the transaction, Dukes Iain D. now holds 54,000 shares, worth roughly $0.74 million.
Goldman initiated its Iovance Biotherapeutics Inc [IOVA] rating to a Buy in a research note published on November 20, 2023; the price target was $12. A number of analysts have revised their coverage, including Barclays’s analysts, who remained covering the stock and in mid September has reiterated a ‘”an Overweight”‘ rating for it. Wells Fargo also remained covering IOVA and has increased its forecast on May 30, 2023 with a “an Overweight” recommendation from previously “an Equal weight” rating.
Price Performance Review of IOVA
On Friday, Iovance Biotherapeutics Inc [NASDAQ:IOVA] saw its stock jump 5.82% to $13.63. Over the last five days, the stock has gained 17.10%. Iovance Biotherapeutics Inc shares have risen nearly 67.65% since the year began. Nevertheless, the stocks have risen 108.73% over the past one year. While a 52-week high of $18.33 was reached on 02/28/24, a 52-week low of $3.21 was recorded on 01/29/24. SMA at 50 days reached $13.99, while 200 days put it at $8.36. A total of 4.29 million shares were traded, compared to the trading of 4.16 million shares in the previous session.
Levels Of Support And Resistance For IOVA Stock
The 24-hour chart illustrates a support level at 13.33, which if violated will result in even more drops to 13.02. On the upside, there is a resistance level at 13.91. A further resistance level may holdings at 14.18. The Relative Strength Index (RSI) on the 14-day chart is 59.83, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.03, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 8.71%. Stochastics %K at 85.22% indicates the stock is a selling.
